DRUG QUANTITY MANAGEMENT POLICY – PER DAYS

POLICY: Multiple Sclerosis – Ocrevus Drug Quantity Management Policy – Per Days
- Ocrevus® (ocrelizumab intravenous infusion – Genentech/Roche)

REVIEW DATE: 06/08/2022

OVERVIEW

Ocrevus is a CD20-directed cytolytic antibody indicated for the treatment of adults with:[1]

- **Relapsing forms of multiple sclerosis** (MS) to include clinically isolated syndrome, relapsing remitting MS, and active secondary progressive MS.
- **Primary progressive MS**.

Dosing

Ocrevus should be administered under the close supervision of an experienced healthcare professional who has access to appropriate medical support to manage severe reactions such as serious infusion reactions.[1] The recommended initial dose of Ocrevus is a 300 mg intravenous (IV) infusion, followed 2 weeks later by a second 300 mg IV infusion. Subsequently, Ocrevus is given as a 600 mg IV infusion once every 6 months.

Availability

Ocrevus is available as 300 mg/10 mL single-dose vials in cartons containing one vial each.[1]

POLICY STATEMENT

This Drug Quantity Management program has been developed to promote the safe, effective, and economic use of Ocrevus. If the Drug Quantity Management rule is not met for the requested medication at the point of service, coverage will be determined by the Criteria below. All approvals are provided for the duration noted below.

Automation: None.

Drug Quantity Limits

Product	Strength	Maximum Quantity per 180 Days
Ocrevus® (ocrelizumab intravenous infusion)	300 mg/10 mL vials	2 vials (total of 600 mg/20 mL)

CRITERIA

1. If the patient is initiating treatment with Ocrevus or requires additional induction dosing, approve a one-time override for two 300 mg/10 mL vials.

REFERENCES

1. Ocrevus® intravenous infusion [prescribing information]. San Francisco, CA: Genentech/Roche; March 2021.